98%
921
2 minutes
20
Objective: We report mortality outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) among people with type 2 diabetes diagnosed within 10 years and no recent history of cardiovascular events or cancer.
Research Design And Methods: Overall mortality rates and major causes of death were assessed over an average of 5 years of follow-up. Cause of death was adjudicated centrally by a committee masked to treatment assignment. We examined baseline covariates and the 10-year Framingham Risk Score for associations.
Results: Mortality rate was low (0.59 per 100 participant-years). Participants who died during follow-up were likely to be older, be male, have a history of hypertension, have a history of smoking, and have moderate albuminuria. The two most common underlying causes of death were "cardiovascular-cause" (a composite of underlying causes) (38.6%) and cancer (26.8%). There were no differences by treatment group.
Conclusions: Among people with diabetes of relatively short duration, cause of death was varied. Attention to health risks beyond cardiovascular diseases is warranted.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10973919 | PMC |
http://dx.doi.org/10.2337/dc23-1356 | DOI Listing |
Diabetes Res Clin Pract
September 2025
Siriraj Population Health and Nutrition Research Group (SPHERE), Research Group and Research Network Division, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. Electronic address:
Aims: Low-carbohydrate diets (LCDs) have emerged as a potential dietary intervention for managing glycemic control, but their effectiveness across different cultural contexts remains unclear. To evaluate the efficacy of LCDs in managing type 2 diabetes, with attention to cultural context, and to clarify how variability in carbohydrate definitions affects interpretation.
Methods: We searched PubMed, Embase, and Scopus from inception to 1 August 2024 for randomized controlled trials (RCTs) ≥ 12 weeks in adults with type 2 diabetes.
Front Nutr
August 2025
Plants for Human Health Institute, North Carolina State University, Kannapolis, NC, United States.
Background And Objective: Combining natural compounds with conventional drugs is an emerging strategy to improve the management of type 2 diabetes and its precursor, prediabetes. While metformin effectively lowers blood glucose and improves insulin sensitivity, it may cause side effects or lose efficacy over time. Natural agents, particularly polyphenols, are being explored as adjunct therapies to enhance glycemic control, mitigate adverse effects, and slow disease progression.
View Article and Find Full Text PDFDiabetes Ther
August 2025
Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy.
Despite advances in cardiovascular risk reduction in type 2 diabetes (T2D), a persistent gap remains compared to individuals without diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1RA) have provided consistent cardiovascular benefits. With more cardiovascular protective agents available for diabetes management, their incremental effect may be nearing a ceiling.
View Article and Find Full Text PDFInt J Environ Res Public Health
August 2025
Grupo de Pesquisa em Exercício Clínico (GPEC), Centro de Desportos, Universidade Federal de Santa Catarina, R. Deputado Antônio Edu Vieira, Pantanal, Florianópolis 88040-001, Brazil.
Introduction: There is a lack of knowledge regarding the acute glycemic and blood pressure responses to resistance exercises that involve different amounts of muscle mass.
Objective: To analyze the acute effects of single- and multi-joint resistance exercises on glycemic control and blood pressure in individuals with type 2 diabetes (T2DM).
Methods: This is a pilot randomized crossover trial, including adults with T2DM of both genders.
Anal Chem
September 2025
Chemistry Faculty of M.V. Lomonosov, Moscow State University, Leninskie Gory, 1/3, Moscow 119991, Russia.
We report on the Prussian Blue (PB) and glucose oxidase (GOx) based first-generation biosensor with a linear calibration range remarkably extended to high concentrations, which is suitable for continuous monitoring in oxygen-deficient media. The increase of the apparent Michaelis constant by several orders of magnitude, resulting in a record linear range, was achieved by reduction of the GOx amount immobilized in the sensor membrane. The latter allowed one to diminish the O deficiency and keep its transport in pace with glucose oxidation.
View Article and Find Full Text PDF